我要投票 瑞阳在中草药行业中的票数:5
· 外 推 电 报 ·
2024-11-22 09:22:47 星期五

【瑞阳是哪个国家的品牌?】

瑞阳是什么牌子?「瑞阳」是 瑞阳制药有限公司 旗下著名品牌。该品牌发源于山东,由创始人苗得足在1998-03-20期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

瑞阳制药有限公司创建于1966年,是山东省第一家粉针剂生产企业。四十多年来,瑞阳制药有限公司秉承“瑞阳制药,造福四方”的经营宗旨,坚持创新为本、品质至上、内强管理、外树品牌、凝聚精英、开放共赢的经营策略,“忠诚守信,坚韧不拔,吃苦耐劳,创新进取”,从一个备战备荒的三线企业,成长为中国医药三十强企业,2010年公司效益位居全国医药工业企业21位。

公司现有总资产40亿余元,员工4000余人。设有国家级企业技术中心、山东省头孢类原料药工程技术研究中心和国家博士后科研工作站,是国家高新技术企业、国家生物医药产业化骨干企业、全国守合同重信用企业、中国专利山东省明星企业。

公司拥有粉针制剂、原料药、固体制剂和中药制剂等20多个生产车间且全部通过国家药品GMP认证。公司还通过了IS09001、ISO14001和OHS18001国际质量、环境、职业健康安全管理体系认证。公司产品有10大类近400个品种规格,年产粉针(冻干)制剂25亿瓶、固体制剂100亿片/粒、合成无菌原料药2000吨、小容量注射剂3亿支。

持续创新是瑞阳制药不断发展的动力之源。瑞阳制药通过加强产品创新、技术创新、营销创新和管理创新形成了自己的发展特点,取得了较快的发展。公司先后与清华大学、山东大学、沈阳药科大学、天津大学、上海医工院、山东医科院等30多家高校和科研机构建立了常年科研合作关系。分别在公司总部、济南、上海和美国设立了四个研发中心,公司的研发能力和技术水平不断提高。

截止目前,公司先后获得国家科技进步二等奖1项、承担国家新药创新重大专项2项,国家级火炬计划项目3项;获得70余项专利证书、60多个新药证书。其中:注射用美洛西林钠制剂及原料药等7个产品通过了山东省科技成果鉴定,有4项填补国内空白,技术水平达到国际领先水平;新药葛根汤颗粒、厚朴排气合剂被认定为“国家重点新产品”。公司的粉针制剂分装水平、中药提取水平和头孢类原料药合成技术均达到国内领先水平。

瑞阳制药坚持以市场为中心,突出抓好营销工作。目前瑞阳制药拥有一支1000余人的专业营销队伍,160多个办事处遍布全国各大中城市,产品已覆盖全国,并远销德、法、韩等30多个国家。

严密的质保体系是瑞阳制药发展的保障。一直以来,无论外在竞争环境如何变化,瑞阳制药始终以严谨、务实的态度,努力从提高产品质量上下工夫,不断提高产品品质,铸造“瑞阳”品牌。瑞阳制药坚守“质量就是天”的诺言,严格按照《药品管理法》、《药品生产质量管理规范》等法律法规的要求组织生产。拥有专业质量检查、监督人员300多人,具有现代化的质量检验中心和先进的监测手段,还通过了山东省质量技术监督局“测量设备计量体系认证”。公司先后负责起草了美洛西林钠、瓦松栓、厚朴排气合剂等42个新药产品的国家药品标准。2010年9月,被国家卫生部药典委授予《中国药典》2010年版标准研究先进单位。

为提高公司信息化管理水平,自2003年以来,公司在主干为千兆的信息平台之上,先后投资1500多万元实施了ERP(企业资源计划)、BPM(项目流程)、HR(人力资源)管理系统、E-MAIL(电子邮件)系统、TPI信息查询系统、网络视频会议和视频监控系统等计算机局域网综合应用项目。先进管理手段的运用,意味着瑞阳公司已经步入企业管理数字化、决策依据数据化的时代。

瑞阳制药在加快企业发展的同时,关注、关心社会公益事业及社会的发展。每年对贫困地区的捐款、对红十字协会的救灾捐助达数百万元,以实际行动,造福百姓、造福四方。近年来,瑞阳制药先后被认定为“山东省医药行业发展突出贡献企业”、“建国60周年山东省医药行业功勋企业”、“新中国60年山东百家领袖品牌”。

瑞阳制药将一如既往地坚持创新为本、品质至上、内强管理、外树品牌、凝聚精英、开放共赢的经营理念,顺国家大势而为,精心打造瑞阳品牌,实现更高质量的成长。

英文翻译:Ruiyang Pharmaceutical Co., Ltd., founded in 1966, is the first powder injection manufacturer in Shandong Province. Over the past 40 years, Ruiyang Pharmaceutical Co., Ltd. has been adhering to the business tenet of "Ruiyang pharmaceutical, benefit the four sides", adhering to the business strategy of innovation-oriented, quality first, internal strong management, external brand building, cohesion of elites, open and win-win, "loyalty, faithfulness, perseverance, hard work, innovation and enterprising", growing from a third-line enterprise ready for war and famine, to one of the top 30 Chinese pharmaceutical enterprises In 2010, the company's efficiency ranked 21 in the national pharmaceutical industry enterprises. The company has total assets of more than 4 billion yuan and more than 4000 employees. With national enterprise technology center, Shandong cephalosporin API engineering technology research center and National Postdoctoral research workstation, it is a national high-tech enterprise, national biomedical industrialization backbone enterprise, national contract abiding and trustworthy enterprise, and a star enterprise in Shandong Province with Chinese patent. The company has more than 20 production workshops including powder injection preparation, API, solid preparation and traditional Chinese medicine preparation, all of which have passed the GMP certification. The company also passed IS09001, ISO14001 and ohs18001 international quality, environment, occupational health and safety management system certification. The company has 10 categories and nearly 400 specifications, with an annual output of 2.5 billion bottles of powder (freeze-dried) preparations, 10 billion tablets / granules of solid preparations, 2000 tons of synthetic sterile APIs, and 300 million small volume injections. Continuous innovation is the driving force for the continuous development of Ruiyang pharmaceutical. Through strengthening product innovation, technology innovation, marketing innovation and management innovation, Ruiyang pharmaceutical has formed its own development characteristics and achieved rapid development. The company has established a long-term scientific research cooperation relationship with more than 30 universities and scientific research institutions, including Tsinghua University, Shandong University, Shenyang Pharmaceutical University, Tianjin University, Shanghai Institute of medical technology, Shandong Medical College, etc. Four R & D centers have been set up in the company headquarters, Ji'nan, Shanghai and the United States. Up to now, the company has won one second prize of national science and technology progress, two major national new drug innovation projects, three national Torch Program projects, more than 70 patent certificates and more than 60 new drug certificates. Among them, 7 products, such as meloxicillin sodium for injection and APIs, have passed the appraisal of scientific and technological achievements in Shandong Province, 4 of which have filled the gaps in China, and the technical level has reached the international leading level; the new drug Gegen Tang granules and Houpu exhaust mixture have been recognized as "national key new products". The company's powder injection preparation sub packaging level, Chinese medicine extraction level and cephalosporin API synthesis technology have reached the domestic leading level. Ruiyang pharmaceutical insists on taking the market as the center and focuses on the marketing work. At present, Ruiyang pharmaceutical has a professional marketing team of more than 1000 people, more than 160 offices all over the country's large and medium-sized cities, products have covered the country, and are exported to more than 30 countries, such as Germany, France, South Korea, etc. Strict quality assurance system is the guarantee for the development of Ruiyang pharmaceutical. All along, no matter how the external competitive environment changes, Ruiyang pharmaceutical has always been rigorous, pragmatic attitude, and strive to improve product quality, constantly improve product quality, and create "Ruiyang" brand. Ruiyang pharmaceutical adheres to the promise of "quality is heaven", and organizes production in strict accordance with the requirements of laws and regulations such as the drug management law and the drug production quality management standard. With more than 300 professional quality inspection and supervision personnel, modern quality inspection center and advanced monitoring means, it has also passed the "measurement system certification of measuring equipment" of Shandong Provincial Bureau of quality and technical supervision. The company has been responsible for drafting the national drug standards for 42 new drug products, such as mezlocillin sodium, vasone suppository, Houpu exhaust mixture, etc. In September 2010, it was awarded the advanced unit of standard research of 2010 edition of Chinese Pharmacopoeia by the Pharmacopoeia Committee of the Ministry of health. In order to improve the information management level of the company, since 2003, the company has invested more than 15 million yuan to implement ERP (enterprise resource plan), BPM (project process), HR (human resource) management system, e-mail (e-mail) system, TPI information query system, network video conference and video monitoring system and other computer LAN Integrated Systems on the basis of the information platform with the backbone of Gigabit Joint application project. The application of advanced management means means that Ruiyang company has entered the era of digitalization of enterprise management and digitalization of decision-making basis. While accelerating the development of enterprises, Ruiyang pharmaceutical pays attention to and cares about the social public welfare and social development. Every year, donations to poverty-stricken areas and the Red Cross Society for disaster relief amount to millions of yuan, benefiting the people and the Quartet through practical actions. In recent years, Ruiyang pharmaceutical has been recognized as "Shandong Pharmaceutical industry development outstanding contribution enterprise", "Shandong Pharmaceutical Industry meritorious enterprise in the 60th anniversary of the founding of the people's Republic of China", "Shandong top 100 leading brands in the 60 years of new China". Ruiyang pharmaceutical will, as always, adhere to the business philosophy of innovation-oriented, quality first, internal strong management, external brand building, cohesion of elites, open and win-win, follow the general trend of the country, carefully build Ruiyang brand, and achieve higher quality growth.

本文链接: https://www.waitui.com/brand/ee4ad6671.html 联系电话:05333221555

千城特选小程序码

7×24h 快讯

核聚变产业受青睐,多家公司早已涉足

近期,国务院国资委在署名文章中提出超前布局梯次培育量子科技、核聚变、生物制造、6G等未来产业,再次点燃市场对核聚变产业的热情。11月20日,上海未来聚变能源科技有限公司成立,从股东结构来看,其背后有上海电气控股集团有限公司等3家上海国资旗下公司力挺。环顾A股市场,多家上市公司已从产业链不同领域涉足核聚变赛道。昨日,不少投资者在互动平台密集追问旭光电子、合锻智能等上市公司在核聚变领域的技术、产品、项目等最新进展。(上证报)

2小时前

服装零售商Gap上调全年业绩预期

据报道,服装零售商Gap上调了全年业绩预期,预计本财年销售额将增长1.5%至2%,而此前的预测是增长不到1%,同时上调的还有毛利率和营业收入预测。公司首席执行官理查德·迪克森在接受采访时表示,“从根本上讲,我们的业务比去年要好。”他补充说,该公司的品牌正在“跨类别”抢占市场份额。(界面)

2小时前

“谈生意不再藏着掖着”,期现融合推动化工产业链共赢

在化工贸易环节,上游想把价格卖在高位,下游想把价格买在低位,这种情况长期存在。但随着期货工具的引入,贸易商发挥期现综合服务优势,使用基差贸易等新型模式推动产业链从“对立”走向“共赢”。贸易环节实现深度期现融合,是近年来化工产业的一大变化。近年来,受产能投放周期等因素影响,化工品价格波动幅度较大,产业链企业加工利润被显著压缩。这种情况下,头部贸易商运用期货和衍生品工具带动行业合作共赢,在保障产业链供应链安全稳定方面发挥了积极作用。(上证报)

2小时前

中信建投:低碳环保政策持续完善,全面推进资源循环利用

36氪获悉,中信建投研报称,近期,工信部部长金壮龙发表《进一步全面深化工业和信息化领域改革为推进新型工业化注入强大动力》,提出做强绿色制造业,发展绿色低碳产业,完善绿色环保、新能源装备等发展政策。

2小时前

临近年底,A股易主暗流涌动

临近岁末,A股控制权交易市场暗流涌动。直观来看,“易主”案例近期密集浮现。据不完全统计,10月以来,已有18家上市公司披露交易性控制权变动事项(剔除国资无偿划转、家族内部划转等)。其中,基本面向下、现金流趋紧的公司占据多数,不少公司或面临“戴帽”或“保壳”的压力。水面之下,此前几近沉寂的壳交易,已有买方在摩拳擦掌。多位投行人士反映,近期来咨询买壳事宜的人明显多了起来。(上证报)

2小时前

本页详细列出关于百灵鸟的品牌信息,含品牌所属公司介绍,百灵鸟所处行业的品牌地位及优势。
咨询